medwireNews

approvalsWatch: Neurology 201115

European Medicines Agency Approvals

PitolisantPitolisant has been granted a marketing authorisation for the treatment of narcolepsy with or without cataplexy. The first-in-class medicine acts on histamine H3 receptors in the brain to increase histamine release and enhance wakefulness and alertness.